Argo Biopharmaceutical Co., Ltd.
Argo Biopharmaceutical is a privately held siRNA developer based in Shanghai. Its lead candidate BW-20805 is in a global multicentre Phase 2 study in hereditary angioedema, with updated results announced in September 2026.
| Headquarters | Shanghai, China |
|---|---|
| Listing | Private |
| Lead asset / stage | BW-20805 Phase 2 — global multicentre study (HAE) |
| Latest event | Argo announced updated Phase 2 BW-20805 results for presentation at Bradykinin Symposium 2026. |